Question Bank › The knock on the company is going stale

The knock on the company is going stale

The knock on the company is going stale: this quarter's own facts cut against the standing doubt

Calls Tested
287
Answered YES
68
Hit Rate
23.7%
rare by design

Companhia de Saneamento Básico do Estado de São Paulo - SABESP (SBS) — this company's answers

NO on the Q3 2023 call 2023-11-10 C+
The model's full reasoning — Q3 2023 call → NO我们根据要求分析。需要找出一个明确的、公司特定的疑虑,并且本季度的实际运营证据是否反驳了它。 从电话会议中,我们看到几个主题:私有化、监管、坏账、成本削减、能源等。但有一个明显的疑虑:公司正在进行私有化,投资者可能担心监管变化或私有化进程。但更具体的是,关于坏账和收款的问题,以及关于成本削减(如人员)的疑虑。还有关于监管讨论的疑虑。 但我们需要一个“standing knock”——一个长期存在的疑虑。在电话中,管理层多次提到“我们一直在努力”、“我们正在转型”,但具体疑虑是什么?分析师的问题:关于坏账的改善是否可持续,关于监管对话的进展。还有关于私有化进程的疑虑。 另一个可能:公司过去有亏损或业绩不佳?但这里显示增长。 仔细看:管理层提到“我们开始看到所有努力的具体成果”,但这是本季度。疑虑可能是关于公司能否实现效率提升?或者关于私有化后的监管? 但更明确的是:分析师问“allowance for doubtful accounts”是否可持续,以及监管对话。管理层回答时提到“我们正在做结构性工作”,但承认结果会逐渐出现。这似乎不是反驳疑虑,而是承认需要时间。 另一个疑虑:关于私有化,有反对声音(如停电事件后),但管理层说私有化会带来好处,并列举了韧性措施。但这是回应外部质疑,不是本季度运营证据。 也许疑虑是“公司能否实现成本削减目标”?管理层提到IDP计划,但说全面收益要到2024年7月。这也不是本季度证据。 再读:管理层强调“本季度开始看到具体成果”,比如收入增长、坏账改善、能源效率等。但疑虑是什么? 或许疑虑是“公司能否在私有化前改善业绩”?但这不是明确提出的。 另一个角度:公司有大量投资,折旧增加,但收入增长。疑虑可能是“投资回报能否实现”?但管理层没有直接回应。 我认为最接近的是:关于坏账的疑虑——公司过去有高坏账,现在改善,但管理层承认这是通过收款活动,且结构性工作还在进行。这似乎不是反驳,而是部分承认。 或者关于监管:公司向监管机构提交了提案,但等待回应,没有实际结果。 也许疑虑是“公司能否控制成本”?管理层提到人员减少,但效果未完全显现。 再考虑:电话中有一个明确的问题:“IDP expected to deliver a 15% reduction... if not, when?” 管理层说要到2024年7月。这表示疑虑是成本削减能否实现,但本季度没有完全实现,所以不是反驳。 另一个:关于私有化进程,管理层说正在推进,但本季度没有实质事件。 或许疑虑是“公司能否维持增长”?但增长是事实。 我注意到管理层多次提到“我们正在转型”、“我们正在改变”,但具体疑虑是什么? 也许疑虑是“公司是否过度依赖某个客户或市场”?没有提到。 或者“公司能否应对监管变化”?但那是未来。 我认为没有明确的、公司特定的、长期存在的疑虑被本季度证据反驳。管理层更多是在描述进展,而不是回应一个具体的怀疑。 但有一个:分析师问“allowance for doubtful accounts”是否可持续,管理层说“我们正在做结构性工作”,但承认结果会逐渐出现。这似乎没有反驳,而是承认疑虑。 另一个:关于监管对话,管理层说“我们提交了提案,等待回应”,没有结果。 所以,可能没有符合的。 再仔细看:管理层提到“我们开始看到所有努力的具体成果”,但这是总体。 也许疑虑是“公司能否在私有化前改善业绩”?但管理层没有直接回应。 我认为答案应该是NO,因为没有明确的、被本季度证据反驳的疑虑。 但让我们再确认:是否有分析师或管理层提到“怀疑”或“担忧”?在电话中,管理层说“我们正在做很多工作”,但没提到具体疑虑。 也许疑虑是“公司能否实现效率提升”?但管理层说“我们正在实施”,但本季度证据是收入增长、坏账改善等,但这些都是本季度发生的,可以视为反驳。 但疑虑是否“长期存在”?从电话中看,管理层在回应分析师关于坏账和监管的问题,这些可能是投资者关心的。 但管理层回答坏账时,说“我们正在做结构性工作”,并提到收款活动,但承认“结果会逐渐出现”。这似乎不是反驳,而是承认需要时间。 对于监管,管理层说“我们提交了提案,等待回应”,没有结果。 所以,没有明确的“本季度实际活动”反驳疑虑。 因此,答案应为NO。 但让我们再读一遍:管理层说“本季度开始看到具体成果”,比如收入增长3.3%,坏账改善等。这些是实际发生的。但疑虑是什么?也许疑虑是“公司能否控制坏账”?但管理层说改善是来自收款活动,且结构性工作还在进行,所以不是完全反驳。 也许疑虑是“公司能否在私有化前保持业绩”?但没提到。 我认为没有。 所以回答NO。

← Back to the full SBS analysis

Show the exact prompt the model was given
Using ONLY the supplied earnings call transcript and no outside information: Reading this call as a whole, can you identify ONE well-defined DOUBT that has clearly been weighing on how this company is perceived — a standing knock evident from the transcript itself, such as skepticism that its losses will ever end, that its main product or model will find repeat demand, that its legacy business's decline will swamp everything else, that it depends too heavily on one customer, market, or financing source, or another comparable company-specific concern — AND does the CURRENT PERIOD'S OWN OPERATING EVIDENCE, as recounted by management, move clearly AGAINST that doubt? Answer YES when BOTH halves come through in the transcript, in whatever form fits the business: (1) A STANDING, COMPANY-SPECIFIC DOUBT IS VISIBLE ON THE CALL. The transcript itself shows that a particular concern has hung over this company — through analysts returning to it, management acknowledging what skeptics or investors have worried about, or management plainly addressing a question it knows the audience carries (can this business make money, will anyone buy this at scale, will the decline stop, can they fund themselves, will the big customer stay). The doubt must be specific to this company's situation, not generic macro gloom, and must read as something that predates this quarter rather than arising on this call. (2) THIS PERIOD'S REAL ACTIVITY CUTS AGAINST IT. Management recounts concrete things that actually happened in the recent period — actual orders, customers returning or expanding, real revenue or volumes where there had been little, losses narrowing because of how the business itself is now running, the doubted product performing in real use, the feared departure or decline not occurring while something better did — described with enough operating substance that the contradiction rests on observed events rather than on reassurance, plans, or projections. The evidence need not fully settle the doubt; what matters is that the current period's facts point the other way and management engages the doubt with those facts. Answer NO if no company-specific doubt is discernible — an ordinarily healthy company reporting a routine quarter. NO if the doubt exists but management answers it mainly with confidence, vision, targets, or hoped-for improvements rather than with things that already happened. NO if the period's evidence actually confirms the doubt (the losses widened, the decline continued, the customer left) and management is excusing it. NO if the contrary evidence is a one-time item, an asset sale, a financing, or something management itself treats as non-recurring rather than the business operating differently. NO if the doubt and the evidence never connect — strong facts reported on one topic while the standing concern sits elsewhere untouched. NO if the doubt appears only as boilerplate risk language or an analyst aside that management never engages. Use only the supplied transcript. Answer only YES or NO.

Companies that answered YES

TickerCompanyCallDateCall grade
CRGO Freightos Limited Q1 2024 2024-05-20 C+
IFS Intercorp Financial Services Inc. Q1 2024 2024-05-14 C+
PRA ProAssurance Corporation Q1 2024 2024-05-11 D
LTRX Lantronix, Inc. Q3 2024 2024-04-29 C
ASB Associated Banc-Corp Q1 2024 2024-04-25 A
GL Globe Life Inc. Q1 2024 2024-04-23 F
ASM Avino Silver & Gold Mines Ltd. Q4 2023 2024-03-21 C+
KOPN Kopin Corporation Q4 2023 2024-03-14 C+
GIII G-III Apparel Group, Ltd. Q4 2024 2024-03-14 C
HP Helmerich & Payne, Inc. Q1 2024 2024-01-30 C
PFE Pfizer Inc. Q4 2023 2024-01-30 F
QTRX Quanterix Corporation Q3 2023 2023-11-07 B
ALL The Allstate Corporation Q3 2023 2023-11-02 C+
DASH DoorDash, Inc. Q3 2023 2023-11-01 C+
PTN Palatin Technologies, Inc. Q4 2023 2023-09-29 D
BZUN Baozun Inc. Q2 2023 2023-08-28 D
GVP GSE Systems, Inc. Q1 2023 2023-05-15 D
BXSL Blackstone Secured Lending Fund Q1 2023 2023-05-10 A
FTHM Fathom Holdings, Inc. Q1 2023 2023-05-10 C
SPIR Spire Global, Inc. Q1 2023 2023-05-10 B
SBRA Sabra Health Care REIT, Inc. Q1 2023 2023-05-04 B
BRX Brixmor Property Group Inc. Q1 2023 2023-05-02 A
TACT TransAct Technologies Incorporated Q4 2022 2023-03-08 A
VRE Veris Residential, Inc. Q4 2022 2023-02-22 D
TOST Toast, Inc. Q4 2022 2023-02-16 C+
PKOH Park-Ohio Holdings Corp. Q3 2022 2022-11-13 B
CLSD Clearside Biomedical, Inc. Q3 2022 2022-11-09 C
SIBN SI-BONE, Inc. Q3 2022 2022-11-07 C+
CHE Chemed Corporation Q3 2022 2022-11-01 B+
YMM Full Truck Alliance Co. Ltd. Q2 2022 2022-08-25 C+
EXFY Expensify, Inc. Q2 2022 2022-08-12 D
WD Walker & Dunlop, Inc. Q2 2022 2022-08-09 C+
DM Desktop Metal, Inc. Q2 2022 2022-08-08 F
XHR Xenia Hotels & Resorts, Inc. Q2 2022 2022-08-05 A
LIN Linde plc Q2 2022 2022-07-28 B+
CME CME Group Inc. Q2 2022 2022-07-27 B
OGI OrganiGram Holdings Inc. Q3 2022 2022-07-14 B+
SE Sea Limited Q1 2022 2022-05-17 F
VNRX VolitionRx Limited Q1 2022 2022-05-12 F
OPK OPKO Health, Inc. Q1 2022 2022-05-09 D
FARM Farmer Bros. Co. Q3 2022 2022-05-07 D
BFIN BankFinancial Corporation Q1 2022 2022-05-06 A
BXP Boston Properties, Inc. Q1 2022 2022-05-03 A
STC Stewart Information Services Corporation Q1 2022 2022-04-29 C+
LOW Lowe's Companies, Inc. Q3 2021 2021-11-17 B+
CYBR CyberArk Software Ltd. Q3 2021 2021-11-04 B+
IPGP IPG Photonics Corporation Q3 2021 2021-11-02 C
SXC SunCoke Energy, Inc. Q3 2021 2021-11-01 A
EMR Emerson Electric Co. Q3 2021 2021-08-04 B+
EEX Emerald Holding, Inc. Q2 2021 2021-08-01 C+
GECC Great Elm Capital Corporation Q3 2018 2018-11-13 B
UMH UMH Properties, Inc. Q3 2018 2018-11-02 C+
FOSL Fossil Group, Inc. Q1 2018 2018-05-08 C
BCOV Brightcove Inc. Q1 2018 2018-04-26 B+
AVT Avnet, Inc. Q2 2018 2018-01-25 B
PII Polaris Inc. Q3 2017 2017-10-24 C+
GNTX Gentex Corporation Q3 2017 2017-10-20 B
MTG MGIC Investment Corporation Q3 2017 2017-10-18 B+
LIND Lindblad Expeditions Holdings, Inc. Q2 2017 2017-08-06 C
BIIB Biogen Inc. Q2 2017 2017-07-25 B
CAG Conagra Brands, Inc. Q2 2017 2016-12-22 C+
WYY WidePoint Corporation Q3 2016 2016-11-09 D
ULBI Ultralife Corporation Q3 2016 2016-10-29 C+
ARAY Accuray Incorporated Q4 2016 2016-08-17 B
GES Guess?, Inc. Q1 2017 2016-05-25 F
RCL Royal Caribbean Cruises Ltd. Q1 2016 2016-04-29 C+
DD DuPont de Nemours, Inc. Q1 2016 2016-04-26 B+
HPP Hudson Pacific Properties, Inc. Q4 2015 2016-02-25 C

How the model reasoned

BRX · Q1 2023 → YESThe question asks if there's a standing company-specific doubt visible on the call, and if this period's operating evidence cuts against it. YES The standing doubt is the skepticism that tenant disruptions (especially bankruptcies like Bed Bath) will create occupancy pressure and throw markets out of equilibrium, given the recaptured space and potential for more filings. This is visible in analyst questions (Todd Thomas on Bed Bath impact and market equilibrium; others circling back on bad debt 75-110 bps and bankruptcy activity) and management's acknowledgment that "recent retailer bankruptcy announcements will result in occupancy pressure" while noting they've "been preparing for the last several quarters." This period's evidence cuts against it: record 94% total occupancy (up sequentially in a seasonally weak quarter), small-shop at 89.
CME · Q2 2022 → YESThe question is: Identify ONE well-defined DOUBT that has been weighing on the company, and see if the current period's operating evidence moves against that doubt. YES The standing doubt is the perceived risk that the legacy NEX Group businesses (BrokerTec and EBS) would continue to show range-bound revenue and fail to deliver meaningful growth despite a constructive macro backdrop, as directly raised by Alex Blostein. Management engages this concern head-on by recounting concrete operating evidence from 2Q: BrokerTec US treasuries ADV up 14% YoY, US repo up 25% YoY, EU repo up 14% YoY, plus $4.5 billion in new cross-sell volume from previously non-trading clients and record RV trading volumes of $2.4 billion; 90% of the migration to Globex is complete, with the remaining EBS migration also finished and system enhancements underway.
BXSL · Q1 2023 → YESThe question asks if there's a standing company-specific doubt visible in the transcript, and if this period's operating evidence moves against it. YES The standing doubt visible in the transcript is the skepticism that BXSL’s credit performance will be materially worse than the broader private-credit market because of its exposure to higher-rate environments and the “tails” of the portfolio (i.e., the small slice of companies whose interest-coverage ratios could fall below 1× when 5 % rates are stress-tested). Management itself flags this concern by noting that “it is less about averages… much more about the tails” and that investors keep asking about the percentage of the portfolio below 1× ICR. This quarter’s operating evidence directly counters that doubt: - 0.

More from the question bank

Acted like it's already biggerBetting on a claim they haven't proven yetMoney already collected for work not yet donNew faces on the callThe streak is aliveCommitted past the numbersAll questions →
Not investment advice. Artul.ai publishes AI-generated earnings-call quality grades and expected-volatility estimates — never buy or sell recommendations. We tested over 1,600 predictive hypotheses against 165,000 transcripts; the honest result, including what failed, is documented in our methodology.